Cargando…

Antibody drug conjugates: hitting the mark in pancreatic cancer?

Pancreatic cancer is one of the most common causes of cancer-related death, and the 5-year survival rate has only improved marginally over the last decade. Late detection of the disease means that in most cases the disease has advanced locally and/or metastasized, and curative surgery is not possibl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wittwer, Nicole L., Brown, Michael P., Liapis, Vasilios, Staudacher, Alexander H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598980/ https://www.ncbi.nlm.nih.gov/pubmed/37880707 http://dx.doi.org/10.1186/s13046-023-02868-x

Ejemplares similares

An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer
por: Wittwer, Nicole L, et al.
Publicado: (2023)

Therapeutic targeting of tumor hypoxia and necrosis with antibody α-radioconjugates
por: Staudacher, Alexander H, et al.
Publicado: (2018)

Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB®
por: Liapis, Vasilios, et al.
Publicado: (2020)

Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
por: Staudacher, Alexander H, et al.
Publicado: (2017)

The RNA‐binding protein La/SSB associates with radiation‐induced DNA double‐strand breaks in lung cancer cell lines
por: Staudacher, Alexander H., et al.
Publicado: (2021)

Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models
por: Liapis, Vasilios, et al.
Publicado: (2021)

On Target: Environmental Health Messaging That Hits the Mark
por: Nicole, Wendee
Publicado: (2022)

Erratum: “On Target: Environmental Health Messaging That Hits the Mark”
por: Nicole, Wendee
Publicado: (2022)

Prostate cancer biomarkers: Are we hitting the mark?
por: McGrath, Shannon, et al.
Publicado: (2016)

Hit the mark with diffusion-weighted imaging: metastases of rhabdomyosarcoma to the extraocular eye muscles
por: Hassold, Nicole, et al.
Publicado: (2014)

Aluminium Nanoparticles as Efficient Adjuvants Compared to Their Microparticle Counterparts: Current Progress and Perspectives
por: Nazarizadeh, Ali, et al.
Publicado: (2022)

Antibody–drug conjugates as novel anti-cancer chemotherapeutics
por: Peters, Christina, et al.
Publicado: (2015)

A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer
por: Huang, Jing, et al.
Publicado: (2020)

A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer
por: Jin, Yangbing, et al.
Publicado: (2021)

Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
por: Lu, Guolan, et al.
Publicado: (2020)

Antibody-Drug Conjugates in Bladder Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2018)

Public Health Messaging During Extreme Smoke Events: Are We Hitting the Mark?
por: Marfori, M. Therese, et al.
Publicado: (2020)

Antibody–Drug Conjugates for Cancer Therapy
por: Parslow, Adam C., et al.
Publicado: (2016)

Antibody–Drug Conjugates for Cancer Therapy
por: Hafeez, Umbreen, et al.
Publicado: (2020)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

Anti-glypican-1 antibody–drug conjugate is a potential therapy against pancreatic cancer
por: Nishigaki, Takahiko, et al.
Publicado: (2020)

Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer
por: Knapp, Kiley A., et al.
Publicado: (2018)

Release the beams! - Linac4 ready to hit the 50 MeV mark
por: Katarina Anthony
Publicado: (2015)

“Hit‐and‐Run” leaves its mark: Catalyst transcription factors and chromatin modification
por: Varala, Kranthi, et al.
Publicado: (2015)

Fate of Antibody-Drug Conjugates in Cancer Cells
por: Chalouni, Cécile, et al.
Publicado: (2018)

Safety and Tolerability of Antibody-Drug Conjugates in Cancer
por: Wolska-Washer, Anna, et al.
Publicado: (2019)

Treating Prostate Cancer by Antibody–Drug Conjugates
por: Rosellini, Matteo, et al.
Publicado: (2021)

Advances and Limitations of Antibody Drug Conjugates for Cancer
por: Mckertish, Candice Maria, et al.
Publicado: (2021)

Antibody-Drug Conjugates Used in Breast Cancers
por: Abbas, Aram J., et al.
Publicado: (2021)

Antibody–Drug Conjugates for the Treatment of Breast Cancer
por: Corti, Chiara, et al.
Publicado: (2021)

Microtubule inhibitor-based antibody–drug conjugates for cancer therapy
por: Klute, Kelsey, et al.
Publicado: (2014)

Introduction to Antibody-Drug Conjugates
por: Pettinato, Mark C.
Publicado: (2021)

ANTIBODY DRUG CONJUGATES (ADCS)
por: Terpos, E.
Publicado: (2023)

Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer
por: Knutson, Steve, et al.
Publicado: (2016)

Methods to Make Homogenous Antibody Drug Conjugates
por: Kline, Toni, et al.
Publicado: (2014)

Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate
por: Subhan, Md Abdus, et al.
Publicado: (2023)

Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations
por: Shim, Hyunbo
Publicado: (2020)

Site-specific antibody drug conjugates for cancer therapy
por: Panowski, Siler, et al.
Publicado: (2013)

Antibody-drug conjugates—an emerging class of cancer treatment
por: Diamantis, Nikolaos, et al.
Publicado: (2016)

Antibody-drug conjugates: smart weapons against cancer
por: Hayat, Seyed Mohammad Gheibi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_30jqlvie5kkp9cjll18gc8ck4f